Clinical Trials Logo

Skin Toxicity clinical trials

View clinical trials related to Skin Toxicity.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06118047 Recruiting - Clinical trials for Metastatic Colorectal Cancer

Crisaborole Ointment for Skin Toxicity Induced by Cetuximab

COSTIC
Start date: August 1, 2023
Phase: Phase 2
Study type: Interventional

This is a prospective, single-arm, phase II clinical trial that will enroll metastatic colorectal cancer patients with Cetuximab-Related Skin Toxicity, who will receive crisaborole ointment twice daily.

NCT ID: NCT05109858 Recruiting - Skin Toxicity Clinical Trials

Skin Toxicity by Oncological Therapies

SKINTOX
Start date: March 21, 2019
Phase:
Study type: Observational

This is a multicenter, retrospective and prospective observational study. The project involves the collection of clinical data of patients treated with oncological therapies, to evaluate skin toxicities related to oncological treatment.

NCT ID: NCT04929834 Recruiting - Skin Toxicity Clinical Trials

Novel Skin Care for Immunotherapy- Related Dermatologic Toxicities

ImmunoSkin
Start date: October 20, 2021
Phase: N/A
Study type: Interventional

Notwithstanding the continuous progress in cancer treatment, patients with cancer still have to cope with quality of life (QoL) - impairing complications. Especially an extensive spectrum of dermatologic toxicities has been associated with cancer treatments. The number and type of cutaneous toxicities have evolved over the past 50 years, paralleling the development of new immunomodulatory agents. The immunotherapy-related skin toxicities can significantly impede the patient's emotional, physical, social, and financial well-being resulting in a poor QoL. In rare cases of severe cutaneous reactions, treatment modifications are needed, resulting in a diminished overall survival. Important organizations in the field of oncology and supportive care, such as the MASCC, the ASCO, and the ESMO, have developed guidelines for the management of cancer therapy- related cutaneous toxicities based on available scientific evidence. Still, for some interventions, the evidence of recommendation is moderate to insufficient. Therefore, it is essential to elucidate other new potential management strategies for dermatological complications of cancer treatment. Based on the previously mentioned supportive care guidelines for the ImmunoSkin project, two novel skin care products to tackle the cutaneous adverse events of immunotherapy have been developed. The ImmunoSkin project general aim is to evaluate the efficacy of two novel skincare products to manage immunotherapy-related cutaneous toxicities.

NCT ID: NCT04650256 Recruiting - Skin Toxicity Clinical Trials

Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences

Start date: July 1, 2021
Phase: N/A
Study type: Interventional

The purpose of this research is to study a Chinese herbal Complementary and Alternative Medicine (CAM) product for the temporary relief of pain and itching after radiotherapy (RT). This is an over-the-counter product with 1% menthol as an active ingredient.

NCT ID: NCT04469075 Recruiting - Glioblastoma Clinical Trials

Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields

Start date: July 9, 2020
Phase: Phase 2
Study type: Interventional

The participants are being treated with Tumor Treating Fields (TTFields) for malignant glioma, and this type of treatment may cause skin-related side effects. This study will test whether using clindamycin and triamcinolone topical lotions can prevent skin-related side effects of TTFields.